Page 55 - 《中国药科大学学报》2025年第4期

第 56 卷第 4 期 于 晶，等：mRNA 疫苗在癌症免疫治疗中的应用 451

in vaccinology[J]. Nat Rev Drug Discov, 2018, 17(4): 261-279. major determinant of mRNA stability[J]. Cell, 2015, 160(6):
[5] Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vac- 1111-1124.
cines: the next immunotherapy frontier[J]. Nat Cancer, 2022, [25] Xia XH. Detailed dissection and critical evaluation of the Pfiz-
3(8): 911-926. er/BioNTech and Moderna mRNA vaccines[J].
[6] Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA Vaccines(Basel), 2021, 9(7): 734.
vaccine technology[J]. Curr Opin Immunol, 2020, 65: 14-20. [26] O’Brien EP, Ciryam P, Vendruscolo M, et al. Understanding
[7] Schlake T, Thess A, Fotin-Mleczek M, et al. Developing mR- the influence of Codon translation rates on cotranslational pro-
NA-vaccine technologies[J]. RNA Biol, 2012, 9(11): 1319-1330. tein folding[J]. Acc Chem Res, 2014, 47(5): 1536-1544.
[8] Reichmuth AM, Oberli MA, Jaklenec A, et al. mRNA vaccine [27] Atkins JF, Loughran G, Bhatt PR, et al. Ribosomal frameshift-
delivery using lipid nanoparticles[J]. Ther Deliv, 2016, 7(5): ing and transcriptional slippage: from genetic steganography
319-334. and cryptography to adventitious use[J]. Nucleic Acids Res,
[9] Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of 2016, 44(15): 7007-7078.
1
double-stranded RNA and activation of NF-κB by Toll-like re- [28] Mulroney TE, Pöyry T, Yam-Puc JC, et al. N -methylpseu-
ceptor 3[J]. Nature, 2001, 413(6857): 732-738. douridylation of mRNA causes +1 ribosomal frameshifting[J].
[10] Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral respons- Nature, 2024, 625(7993): 189-194.
es by means of TLR7-mediated recognition of single-stranded [29] De Martel C, Georges D, Bray F, et al. Global burden of cancer
RNA[J]. Science, 2004, 303(5663): 1529-1531. attributable to infections in 2018: a worldwide incidence analy-
[11] Heil F, Hemmi H, Hochrein H, et al. Species-specific recogni- sis[J]. Lancet Glob Health, 2020, 8(2): e180-e190.
tion of single-stranded RNA via Toll-like receptor 7 and 8[J]. [30] Hillemanns P, Denecke A, Woelber L, et al. A therapeutic anti-
Science, 2004, 303(5663): 1526-1529. gen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-
[12] Islam MA, Rice J, Reesor E, et al. Adjuvant-pulsed mRNA vac- positive high-grade cervical intraepithelial neoplasia: results
cine nanoparticle for immunoprophylactic and therapeutic tu- from a phase I/IIa trial[J]. Clin Cancer Res, 2022, 28(22): 4885-
mor suppression in mice[J]. Biomaterials, 2021, 266: 120431. 4892.
[13] Linares-Fernández S, Lacroix C, Exposito JY, et al. Tailoring [31] Bhuyan PK, Dallas M, Kraynyak K, et al. Durability of re-
mRNA vaccine to balance innate/adaptive immune response[J]. sponse to VGX-3100 treatment of HPV16/18 positive cervical
Trends Mol Med, 2020, 26(3): 311-323. HSIL[J]. Hum Vaccin Immunother, 2021, 17(5): 1288-1293.
[14] Paschal BM, McReynolds LA, Noren CJ, et al. RNA poly- [32] Youn JW, Hur SY, Woo JW, et al. Pembrolizumab plus GX-
merases[J]. CP Molecular Biology, 2008, 84(1): 381-388. 188E therapeutic DNA vaccine in patients with HPV-16-posi-
[15] Milligan JF, Groebe DR, Witherell GW, et al. Oligoribonu- tive or HPV-18-positive advanced cervical cancer: interim re-
cleotide synthesis using T7 RNA polymerase and synthetic sults of a single-arm, phase 2 trial[J]. Lancet Oncol, 2020,
DNA templates[J]. Nucleic Acids Res, 1987, 15(21): 8783-8798. 21(12): 1653-1660.
[16] Shatkin AJ, Manley JL. The ends of the affair: capping and [33] Peng SW, Qiu J, Yang A, et al. Optimization of heterologous
polyadenylation[J]. Nat Struct Biol, 2000, 7(10): 838-842. DNA-prime, protein boost regimens and site of vaccination to
[17] Hornung V, Ellegast J, Kim S, et al. 5′-triphosphate RNA is the enhance therapeutic immunity against human papillomavirus-
ligand for RIG-I[J]. Science, 2006, 314(5801): 994-997. associated disease[J]. Cell Biosci, 2016, 6: 16.
[18] Ramanathan A, Robb GB, Chan SH. mRNA capping: biologi- [34] Einstein MH, Roden RBS, Ferrall L, et al. Safety Run-in of in-
cal functions and applications[J]. Nucleic Acids Res, 2016, tramuscular pNGVL4a-sig/E7(detox)/ HSP70 DNA and TA-
16+
44(16): 7511-7526. CIN protein vaccination as treatment for HPV ASC-US,
[19] Karikó K, Buckstein M, Ni HP, et al. Suppression of RNA ASC-H, or LSIL/ CIN1[J]. Cancer Prev Res (Phila), 2023,
recognition by toll-like receptors: the impact of nucleoside mod- 16(4): 219-227.
ification and the evolutionary origin of RNA[J]. Immunity, [35] Klinghammer K, Saba NF, Castelluci E, et al. 155P BNT113 +
2005, 23(2): 165-175. pembrolizumab as first-line treatment in patients with unre-
[20] Karikó K, Muramatsu H, Ludwig J, et al. Generating the opti- sectable recurrent/metastatic HNSCC: Preliminary safety data
mal mRNA for therapy: HPLC purification eliminates immune from AHEAD-MERIT[J]. Immuno Oncol Technol, 2022, 16:
activation and improves translation of nucleoside-modified, pro- 100267.
tein-encoding mRNA[J]. Nucleic Acids Res, 2011, 39(21): e142. [36] Gibson M, Savvides P, Worden F, et al. Phase II trial assessing
[21] Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of safety, efficacy and immune correlates of heterologous prime-
pseudouridine into mRNA yields superior nonimmunogenic boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizum-
vector with increased translational capacity and biological sta- ab for advanced, PD-L1 CPS≥1, hrHPV+ oropharyngeal can-
bility[J]. Mol Ther, 2008, 16(11): 1833-1840. cer[J]. Int J Radiat Oncol, 2024, 118(5): e89-e90.
[22] Asrani KH, Farelli JD, Stahley MR, et al. Optimization of mR- [37] Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than
NA untranslated regions for improved expression of therapeutic 50 years old and still providing surprises[J]. Nat Rev Cancer,
mRNA[J]. RNA Biol, 2018, 15(6): 756-762. 2016, 16(12): 789-802.
[23] Kim SC, Sekhon SS, Shin WR, et al. Modifications of mRNA [38] Rappaport AR, Kyi C, Lane M, et al. A shared neoantigen vac-
vaccine structural elements for improving mRNA stability and cine combined with immune checkpoint blockade for advanced
translation efficiency[J]. Mol Cell Toxicol, 2022, 18(1): 1-8. metastatic solid tumors: phase 1 trial interim results[J]. Nat
[24] Presnyak V, Alhusaini N, Chen YH, et al. Codon optimality is a Med, 2024, 30(4): 1013-1022.